drugset / Trial / NCT03545815

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

NCT03545815

Phase 1 Unknown 10 enrolled Chinese PLA General Hospital
NaSingle-groupOpen-labelTreatment

Summary

Multiple solid tumors have positive targets of mesothelin expressed on the surfaces of the tumor cells, we use the technique of CRISPR-Cas9 to knocked out the PD-1 and TCR of chimeric antigen receptor (CAR) T cells to effect the immuno-microenvironment around tumors.

Timeline

Start
2018-03-19
Primary completion
2020-10-30
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti-mesothelin CAR-T cells Cell therapy Other

Indications